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Trichorhinophalangeal syndrome (TRPS) is a rare genetic disorder with typical craniofacial and skeletal
abnormalities. Three main subtypes have been described. All variations of the condition affect the hair
(tricho), nose (rhino) and ﬁngers (phalangeal). The diagnosis is usually made through clinical examina-
tion augmented by hand radiographs that reveal characteristic cone-shaped epiphyses
Sporadic case reports detailing TRPS have been described in the literature. We describe the ﬁrst
report of high-grade osteosarcoma presenting in two members of the same family with trichorhino-
phalangeal syndrome (TRPS).
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case
A 21-year-old man presented with a three month history of pain
and a lump on his left distal femur. As a child, pediatricians reviewed
him because of his short stature. It was noted that he exhibited the
classical phenotypic characteristic of TRPS; short stature, very sparse
hair with reduced hair growth, and cone shaped epiphyses on
imaging. Furthermore, both his sister and mother also had the same
distinctive appearances. The pediatricians therefore diagnosed our
patient, along with his sister andmother, with an autosomal dominant
inherited form of TRPS. He had no other signiﬁcant medical history.
On presentation to our unit, plain radiographical images of his
left femur revealed a central, rapidly expanding lesion within the
distal femur remote from any pre-existing exostoses. Magnetic
resonance imaging (MRI) of the left femur showed an 8 centimeter
tumor arising in the distal femoral meta-diaphysis with a small
soft tissue component.
Needle biopsy showed an inﬁltrative high-grade, spindle-cell
sarcoma. Although there was no convincing osteoid the features were
suggestive of osteosarcoma. Staging showed no evidence of metastasis
and bone scan conﬁrmed the lesion was solitary.
Two months after referral, our patient was undergoing che-
motherapy consisting of cisplatin, doxorubicin and methotrexate,
when his mother complained of an ache to her right distal femur.
Plain radiographs and MRI revealed a rapidly expanding lesion
within the right distal femur. A needle biopsy conﬁrmed the
diagnosis of a high-grade, osteosarcoma identical to the features
seen in the distal femoral tumor of her son.. This is an open access article und
ns).Cytogenetic analysis of both our index case and his mother's
femoral biopsies by array comparative genomic hybridization
using BlueGnome 0.5 M Cytochip v3.0 BAC array showed whole
chromosome gain of 3, 9 (possibly 2 copies), 11, 14, 15 and 22.
Segmental or interstitial gains included 3p21 (possibly ampliﬁed
or higher level gain), 4p, 5p, 12p, 16p13.2-q13.12, 16q12.1-q13,
17p11.2, 17q21.33-q25, 18pter-p11.21 and 21q11.2-q21.1. Whole
chromosome losses included chromosomes 1, 2, 6, 8, 10 and 13.
Segmental losses included 16q13-q22.1, 17pter-p12 and 18q.
Staging CT of the patient's mother did not show any soft tissue
metastasis but, unfortunately, a bone scan revealed a further,
asymptomatic bony lesion within the left distal femur. This was
conﬁrmed as another high-grade osteosarcoma on needle biopsy.
Chemotherapy was therefore initiated in the form of cisplatin,
doxorubicin and methotrexate.
They both underwent three cycles of chemotherapy prior to
surgical resection of the tumor and distal femoral replacement. The
mother elected to have the symptomatic right distal femur operated
on ﬁrst and, at a later date, and after suitable recovery, the left.
Histological review of both our index case and his mother's
resection specimens revealed 99% post chemotherapy tumor necrosis.
Postoperative chemotherapy was initiated in both patients. Sadly,
prior to undergoing resection of the asymptomatic left femur, the
index case's mother died as a result of chemotherapy complications.
Because of the strong link between TRPS in our family cohort and
osteosarcoma the index case's sister was screened using a bone scan.
This did not reveal any abnormality but regular follow-up is planned.2. Discussion
Trichorhinophalangeal syndrome (TRPS) was ﬁrst described in
1966 by Giedon who delineated a syndrome characterized byer the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
S. Evans et al. / Journal of Bone Oncology 2 (2013) 92–93 93sparse and slowly growing hair, a long pair shaped nose with a
bulbous tip, and ﬁnger deformities [1]. Since Geidon's ﬁrst
descriptions of TRPS, only subsequent small cases series have been
published detailing further phenotypical characteristics along with
attempts to specify the genetic abnormalities.
TRPS can be subdivided into three sub-types with the above
key features expressed in all three [2,3]. The syndrome can have
multi-system involvement with associated endocrine disorders,
renal alterations, heart anomalies and bone dysplasia [1–4].
TRPS I and III are inherited in an autosomal dominant fashion,
while TRPS II are often sporadic cases [4]. Deletions, insertions and
translocations of chromosome 8, speciﬁcally from 8q24.11 to
8q24.13 resulting in haploinsufﬁciency of a speciﬁc zinc ﬁnger
protein that is a putative transcription factor have been indicated
as the causative genetic abnormality [5–7]. In addition to the
genetic anomalies for TRPS I, TRPS II is caused by a further
mutation in the EXT1 gene that spans the TRPS I locus resulting
in multiple cartilaginous exostoses [8–10]. No further cytogenetic
abnormalities have been described in TRPS III; supporting the
theory that TRPS III is on the severe end of the same spectrum as
TRPS I [2].
The diagnosis and sub classiﬁcation of TRPS is, however, based
on clinical and radiological ﬁndings, supported by genetic analysis
in equivocal cases [4].
Orthopedic surgeons are likely to come into contact with these
patients due to their bony deformities of the hands, femoral head
and presence of multiple exostoses that may cause nerve impinge-
ment, joint mobility problems or extreme discomfort [11–13].
The benign exostoses in TRPS have a recognized malignant
potential which have been shown to develop into chondrosarco-
mas [4,13]. Both our index case and his mother demonstrated de
novo high grade osteosarcoma. To our knowledge, this occurrence
has not been described anywhere within the literature.
Our cases highlight that TRPS in general also has the potential
for de novo osteosarcoma. We would suggest plain radiographs
and magnetic resonance imaging of the affected limb, along with
staging bone scintigraphy and computer topography of the chest,
abdomen and pelvis as the ﬁrst radiological investigations of
choice at any center managing a patient with a suspected sinister
exostosis or bone pain in TRPS. Bone biopsy is the gold standard
method of determining the exact nature of any bony lesion as it
provides a tissue diagnosis. Biopsy should be performed at a
reference bone tumor unit that is familiar with the care of
musculoskeletal malignancies and where specialist orthopedic,
radiology, oncology and histopathology expertise can be rapidly
accessed under the auspices of a fully accredited bone sarcoma
multi-disciplinary team.We would advocate that any unit treating a patient with TRPS
who has a suspect bone malignancy follow published guidelines
for the management of bone sarcoma [14].
No recommendations have been published regarding the long
term surveillance of patients with TRPS. Follow-up should take
into account the multi-systemic involvement of the syndrome and
any potential malignant transformation within a pre-existing
exostosis or, as in our cases, de novo malignancy, should be
recognized early thereby promoting the possibility of limb salvage
surgery as a viable, curative option.Conﬂict of Interest Statement
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